Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model

Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal B1876BXD, Buenos Aires, Argentina.
Journal of Cancer Research and Clinical Oncology (Impact Factor: 3.08). 01/2003; 128(12):669-77. DOI: 10.1007/s00432-002-0385-7
Source: PubMed


To examine the role of GM3 monosialoganglioside and sialic acid in the antitumor activity of a vaccine based on GM3, hydrophobically conjugated with the outer-membrane-protein complex from Neisseria meningitidis (GM3/VSSP).
In order to evaluate the relationship between antitumor activity and the presence of GM3 on the surface of tumor cells, we used two murine tumor cell lines with different ganglioside expression. Syngeneic mice were immunized with four i.m. doses of GM3/VSSP (120 micro g) at 14-day intervals and challenged subcutaneously with tumor cells.
B16 melanoma cells showed GM3 on cell surface and GM3-dependent in vitro growth. As expected, preimmunization with the vaccine significantly inhibited tumor formation and prolonged survival in mice challenged with B16 cells. In contrast, no antitumor effect was observed in mice challenged with GM3-negative F3II mammary carcinoma cells. The reactivity of sera from immunized mice against B16 cells was confirmed by flow cytometry and immunoperoxidase staining. Depletion of sialic acid residues from the cell surface completely abolished antibody response against melanoma cells.
These results indicate that the antitumor activity of GM3/VSSP is associated with GM3 expression on tumor cell surface and demonstrate a major role of sialic acid in the humoral response of vaccinated mice.

13 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prophylactic vaccination against human cancer provides a unique opportunity to prevent human suffering for individuals at risk for tumor development. Appropriate vaccines may pose slightly different requirements than vaccines intended for therapeutic use. Prophylactic vaccines will need to prevent tumors far into the future, emphasizing the need to establish solid tumor-specific immunologic memory. Another important issue associated with prophylactic cancer vaccines is the identification of appropriate populations for vaccination. Individuals at risk may include those exposed to oncogenic viruses, those with occupational exposure to tumor promoting agents, and individuals with a family history of cancer. This paper addresses the specific challenges posed to the exciting field of prophylactic cancer vaccine research.
    Expert Review of Anti-infective Therapy 09/2003; 3(4):537-45. DOI:10.1586/14737140.3.4.537 · 2.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review shall present an update in anticancer ganglioside-based immunotherapies, with particular emphasis on molecular vaccines and anti-idiotype mAbs produced by the Center of Molecular Immunology (Havana, Cuba). The project comprises vaccines of N-acetyl or N-glycolylneuraminic acid GM3 ganglioside incorporated into very small proteoliposomes and anti-idiotype antibodies to glycolylated gangliosides. Development of these vaccine preparations from preclinical models of melanoma, breast and lung cancer to human investigation is summarized. A brief discussion on the progress and limitations of present-day clinical trials and future prospects is also included.
    Expert Review of Vaccines 01/2004; 2(6):817-23. DOI:10.1586/14760584.2.6.817 · 4.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Specific stimulation of the immune system against tumor antigens, which may result in elimination of malignant cells, may be performed with the use of vaccines containing a specific native or synthetic tumorassociated antigen. To develop a prototype antitumor vaccine, we synthesized an oligosaccharide fragment of tumor-associated antigen, obtained its conjugate with the protein hemocyanin, and studied the immunogenicity of this conjugate. We developed a technique of immunization of experimental animals by the conjugate and obtained secondary immune response to the tumor antigen with a predominant generation of IgG antibodies (ABs). We showed that the ABs generated after immunization of animals with the use of conjugate reacted with the native tumor-associated antigen. The serum of animals immunized with the conjugate contained IgG1 and IgG3 ABs necessary for specific interaction of macrophages and natural killers with malignant cells; hence, the conjugate may be used as a prototype antitumor vaccine.
    Doklady Biological Sciences 07/2007; 415(1):298-301. DOI:10.1134/S001249660704014X
Show more

Preview (2 Sources)

13 Reads
Available from